The DOI matches its Crossref record; 179 of the 179 references it cites were found in a registry or an index.
Targeting Kv7 Potassium Channels for Epilepsy
Open accessAbstract
Voltage-gated Kv7 potassium channels, particularly Kv7.2 and Kv.7.3 channels, play a critical role in modulating susceptibility to seizures, and mutations in genes that encode these channels cause heterogeneous epilepsy phenotypes. On the basis of this evidence, activation of Kv7.2 and Kv.7.3 channels has long been considered an attractive target in the search for novel antiseizure medications. Ezogabine (retigabine), the first Kv7.2/3 activator introduced in 2011 for the treatment of focal seizures, was withdrawn from the market in 2017 due to declining use after discovery of its association with pigmentation changes in the retina, skin, and mucosae. A novel formulation of ezogabine for pediatric use (XEN496) has been recently investigated in children with KCNQ2-related developmental and epileptic encephalopathy, but the trial was terminated prematurely for reasons unrelated to safety. Among novel Kv7.2/3 openers in clinical development, azetukalner has shown dose-dependent efficacy against drug-resistant focal seizures with a good tolerability profile and no evidence of pigmentation-related adverse effects in early clinical studies, and it is now under investigation in phase III trials for the treatment of focal seizures, generalized tonic-clonic seizures, and major depressive disorder. Another Kv7.2/3 activator, BHV-7000, has completed phase I studies in healthy subjects, with excellent tolerability at plasma drug concentrations that exceed the median effective concentrations in a preclinical model of anticonvulsant activity, but no efficacy data in patients with epilepsy are available to date. Among other Kv7.2/3 activators in clinical development as potential antiseizure medications, pynegabine and CB-003 have completed phase I safety and pharmacokinetic studies, but results have not been yet reported. Overall, interest in targeting Kv7 channels for the treatment of epilepsy and for other indications remains strong. Future breakthroughs in this area could come from exploitation of mechanistic differences in the action of Kv7 activators, and from the development of molecules that combine Kv7 activation with other mechanisms of action.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Fig. 1 Hypothetical mechanism of activation of Kv7 channels by ezogabine. Only two of the four subunits forming the functional channel are shown for simplicity. (A) Under resting conditions, the S4 segment of the voltage-sensing domain (VSD) is positioned toward the intracellular side of the membrane. This configuration is stabilized by calmodulin bridging the core region at the S2–S3 linker [where phosphatidylinositol-4,5-biphosphate (PIP2) also binds] and the C-terminus at two α-helical regions denominated HA and HB. The inner pore gate (IG) is closed, the central cavity (CC) above the IG and below the selectivity filter (SF), is narrow. Although the SF is in a conductive state, no ion can flow through the pore as the IG is closed. (B) Membrane depolarization induces a vertical shift in the S4 segment, which also induces a lateral rotation and an upward motion of the S4–S5 linker. (C) S4 repositioning, and the consequent upward motion of the S4–S5 linker, bends the S6 C-terminal half of an adjacent subunit and leads to widening of the IG and an increased hydration of the CC, triggering K+ conduction. Such processes are also accompanied, and possibly facilitated, by the fact that, upon depolarization, the HA and HB helices in the proximal C-terminus, where calmodulin binds in the closed channel configuration, undergo an almost 180° rotation, causing the HA and S6 helices to join in a continuous helix and calmodulin to be released from its attachment site in the S2–S3 linker, as well as by PIP2 repositioning from the S2–S3 linker to the S4–S5 linker. The positions of the ezogabine binding sites (one per subunit) are indicated relative to the overall structure of the channel. (D) A flat ribbon representation of the ezogabine binding site in a Kv7.2 subunit. The illustration shows the ezogabine molecule and the S5 and S6 transmembrane regions from a single Kv7.2 subunit contributing to the binding site. Ionized hydrogen bonds are shown as dashed-yellow lines. The Trp236 residue, which is critical for ezogabine binding, is indicated, together with Leu299 and Ser303 also contributing to drug-channel interactions. Data are from the Protein Data Bank (7CR2) [56, 60]](https://figures.cochat.ai/paper-figures/654f6ca15dfa40f1846b1b46906384c6/targeting-kv7-potassium-channels-for-epilepsy-figure-1.jpg)

![Fig. 3 Median percent reduction from baseline in focal seizure frequency in patients included in randomized double-blind, placebo-controlled, adjunctive-therapy trials of ezogabine (EZG) in focal epilepsy. Based on data from Porter et al. [111], Brodie et al. [112], and French et al. [113]](https://figures.cochat.ai/paper-figures/003169de242c400e9178410ba6608bcd/targeting-kv7-potassium-channels-for-epilepsy-figure-3.jpg)
![Fig. 4 Responder rates (percent of patients with ≥ 50% reduction in focal seizure frequency from baseline) in patients included in randomized, double-blind, placebo-controlled, adjunctive-therapy trials of ezogabine in focal epilepsy. For the study by Porter et al. [111] responder rate was calculated over the entire double-blind treatment period (titration plus maintenance), whereas for the studies by Brodie et al. [112] and French et al. [113] the responder rates shown in the figure were calculated over the maintenance dose period only](https://figures.cochat.ai/paper-figures/719aa10d545846cbbe7b2f29e465e6ba/targeting-kv7-potassium-channels-for-epilepsy-figure-4.jpg)

![Fig. 6 Median percent reduction from baseline in focal seizure frequency (left panel) and responder rates (percent of participants with ≥ 50% reduction in focal seizure frequency from baseline, right panel) in patients included in the phase 2b randomized, double-blind, placebo-controlled, adjunctive-therapy trial of azetukalner (AZE) in focal epilepsy. Based on data from French et al. [146]](https://figures.cochat.ai/paper-figures/6892d345074d4921a56c0e9e4912a064/targeting-kv7-potassium-channels-for-epilepsy-figure-6.jpg)

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Chronic ezogabine is associated with dose dependent dizziness, somnolence, confusion, urinary retention, and, most notably, blue or purple pigmentation of retina, nails, and skin due to drug and metabolite accumulation in melanin rich tissues [253,258,262].”
From Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery (2026) · cites this paper as [262]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Brain-penetrant exemplars such as Lu AA41178 and SCR2682, pan-Kv7 (KCNQ2–5) potassium-channel activators, demonstrate broad antiexcitability efficacy without major off-target activity, while clinical candidates including azetukalner and BHV-7000, Kv7.2/7.3-selective channel activators, aim to retain efficacy while avoiding pigmentation and urinary liabilities associated with earlier chemotypes [”
From Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery (2026) · cites this paper as [262]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Beyond mood, ezogabine reduces cortical and spinal motor neuron excitability in amyotrophic lateral sclerosis and decreases seizure frequency in refractory epilepsy, demonstrating target engagement in human hyperexcitable states and supporting its transdiagnostic potential to quiet unstable circuits [256,262,263].”
From Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery (2026) · cites this paper as [262]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fisher, R. S., Boas, W. V. E., Blume, W., Elger, C., Genton, P., Lee, P., & Engel, J. (2005) · Epilepsia · doi:10.1111/j.0013-9580.2005.66104.x · Cited by 3,671 · cited 1×
“An epileptic seizure is defined as “a transient occurrence of signs and/or symptoms due to abnormal excessive or synchronous neuronal activity in the brain” [1].”
Beghi, E., Berg, A., Carpio, A., Forsgren, L., Hesdorffer, D. C., Hauser, W. A., Malmgren, K., Shinnar, S., Temkin, N., Thurman, D., et al. (2005) · Epilepsia · doi:10.1111/j.1528-1167.2005.00273_1.x · Cited by 2,296
Coassembly of KVLQT1 and minK (IsK) proteins to form cardiac IKS potassium channel
Sanguinetti, M. C., Curran, M. E., Zou, A., Shen, J., Specter, P. S., Atkinson, D. L., & Keating, M. T. (1996) · Nature · doi:10.1038/384080a0 · Cited by 1,764
Positional cloning of a novel potassium channel gene: KVLQT1 mutations cause cardiac arrhythmias
Wang, Q., Curran, M. E., Splawski, I., Burn, T. C., Millholland, J. M., VanRaay, T. J., Shen, J., Timothy, K. W., Vincent, G. M., de Jager, T., et al. (1996) · Nature Genetics · doi:10.1038/ng0196-17 · Cited by 1,759 · cited 1×
“KCNQ1 mutations are responsible for the most common form of long QT syndrome [43], an arrhythmogenic disorder predisposing to torsades de pointes and ventricular fibrillation.”
Muscarinic suppression of a novel voltage-sensitive K+ current in a vertebrate neurone
Brown, D. A., & Adams, P. R. (1980) · Nature · doi:10.1038/283673a0 · Cited by 1,444 · cited 1×
“…fEPSPs, these slow responses showed long synaptic delays (tenths to hundredths of ms), were long-lasting (many seconds) and were due to acetylcholine binding to M1, M3, or M5 muscarinic receptors, hence the name “M-current (I KM )” [24] for the K + current whose suppression generated sEPSPs [23].”
KCNQ2 and KCNQ3 Potassium Channel Subunits: Molecular Correlates of the M-Channel
Wang, H. (1998) · Science · doi:10.1126/science.282.5395.1890 · Cited by 1,294 · cited 1×
“When co-expressed in frog oocytes, KCNQ2 and KCNQ3 yield voltage-gated K + currents with biophysical and pharmacological properties identical to those of the M-current [31, 32], suggesting that the native ganglionic I KM is carried by an heterotetramer of Kv7.”
A novel potassium channel gene, KCNQ2, is mutated in an inherited epilepsy of newborns
Singh, N. A., Charlier, C., Stauffer, D., DuPont, B. R., Leach, R. J., Melis, R., Ronen, G. M., Bjerre, I., Quattlebaum, T., Murphy, J. V., et al. (1998) · Nature Genetics · doi:10.1038/ng0198-25 · Cited by 1,199 · cited 2×
“The recognition that Kv7 channels determine I KM occurred after discovery of epileptogenic variants in two neuronally expressed genes, KCNQ2 [29] and KCNQ3 [30], respectively encoding Kv7.”
Hyperpolarization-Activated Cation Currents: From Molecules to Physiological Function
Robinson, R. B., & Siegelbaum, S. A. (2003) · Annual Review of Physiology · doi:10.1146/annurev.physiol.65.092101.142734 · Cited by 1,177 · cited 1×
“…(b) a recurrent neuron–astrocyte–neuron excitatory loop [9], (c) faster action potentials repolarization and sodium (Na + ) channels repriming caused by hyperactivation of BK channels [10], or (d) hyperpolarization-activated nonselective cation currents [11], resulting in secondary depolarization.”
A pore mutation in a novel KQT-like potassium channel gene in an idiopathic epilepsy family
Charlier, C., Singh, N. A., Ryan, S. G., Lewis, T. B., Reus, B. E., Leach, R. J., & Leppert, M. (1998) · Nature Genetics · doi:10.1038/ng0198-53 · Cited by 937 · cited 2×
“The recognition that Kv7 channels determine I KM occurred after discovery of epileptogenic variants in two neuronally expressed genes, KCNQ2 [29] and KCNQ3 [30], respectively encoding Kv7.”
Zuberi, S. M., Wirrell, E., Yozawitz, E., Wilmshurst, J. M., Specchio, N., Riney, K., Pressler, R., Auvin, S., Samia, P., Hirsch, E., et al. (2022) · Epilepsia · doi:10.1111/epi.17239 · Cited by 934 · cited 5×
“…frequent drug-resistant seizures (mostly with a tonic component) appearing in the first 3 months of life; abnormalities of posture, tone, or movement; developmental impairment; and an abnormal interictal electroencephalogram (EEG), which may include a burst-suppression or multifocal pattern [63].”
InfluentialSelf-citation
Research works printed but not linked: 7
- Miceli F, Soldovieri MV, Weckhuysen S, et al. KCNQ2-Related Disorders. 2010 Apr 27 [Updated 2022 May 19]. In: Adam MP, Feldman J, Mirzaa GM, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2024. https://www.ncbi.nlm.nih.gov/books/NBK32534/.
- Pressler R, Taglialatela M, Plouin P, Hassn H. Self-limited (familial) neonatal epilepsy. In: Engel J Jr, Moshé SL, editors, Epilepsy. A Comprehensive Textbook, 3rd edition, Volume 3, Chapter 275, Philadephia: Wolters Kluwer 2024. p. 2817–26
- Tandy MD, Cadieux JA, Namdari R. Using modified QbD to develop a novel pediatric formulation of ezogabine. Pharm Technol. 2021;45:44–9. https://www.pharmtech.com/view/using-modified-qbd-to-develop-a-novelpediatric-formulation-of-ezogabine. Accessed 15 Aug 2024.
- Goldberg YP. XEN1101, a novel modulator of Kv7.2/3 for the treatment of epilepsy. Slide presentation at the Epilepsy Foundation Pipeline Conference, San Francisco, February 22-23, 2018. https://www.xenon-pharma.com/wp-content/uploads/2018/05/XEN1101_EpilepsyFoundationPresentation_February2018.pdf. Accessed 20 Aug 2024.
- French J, Porter R, Perucca E, Brodie M, Rogawski M, Harden C, Qian J, Rosenblut CL, Kenney C, Beatch GN. Axetukalner (XEN1101), a novel, potent, Kv7 potassium channel opener: Interim data from an ongoing, long-term open-label extension of a phase 2b study (X- TOLE) in adults with focal onset seizures. Poster presented at the 15th European Epilepsy Congress, September 7–11, 2024, Rome, Italy. https://www.xenon-pharma.com/wp-content/uploads/2024/09/EEC24French.pdfy. Accessed 22 Aug 2024. · DOI
- Picchione K, Resnick L, Bozik M, Dworetzky S. Characterization of BHV-7000: a novel Kv7.2/7.3 activator for the treatment of seizures. Presented at the American Academy of Neurology Annual Meeting, Denver, CO, April 13-18, 2024. Neurology 102 (suppl 1). https://doi.org/10.1212/WNL.0000000000206250. · DOI
- Adis International Ltd. CB 03. AdisInsight, updated 3 October 2024. https://adisinsight.springer.com/drugs/800057520. Accessed 20 Oct 2024.
Cited by
Recent advances in the pharmacology of voltage-gated ion channels
Mateos, D. L., Harris, B. J., Hernández-González, A., Yarov-Yarovoy, V. M., & Wulff, H. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100090 · Cited by 31
“142 After some attempts at repurposing of retigabine for ALS in a phase II clinic trial (NCT02450552), where it was shown to reduce cortical and spinal motor neuron hyperexcitability in ALS patients using transcranial magnetic stimulation, 143 or reformulation as XEN496 for KCNQ2 -related DEE and…”
InfluentialVoltage-Gated Ion Channels in Neuropathic Pain Signaling
Felix, R., Corzo-López, A., & Sandoval, A. (2025) · Life · doi:10.3390/life15060888 · Cited by 30
“Likewise, BHV-7000 is a late-stage drug candidate that selectively activates K V 7.2/7.3 potassium channels, primarily developed for epilepsy and mood disorders, with ongoing exploration for pain treatment [295].”
InfluentialPrecision therapies for genetic epilepsies in 2025: Promises and pitfalls
Wang, S., Perucca, E., Berkovic, S. F., & Perucca, P. (2025) · Epilepsia Open · doi:10.1002/epi4.70065 · Cited by 25
Self-citationLiu, X., Yu, Y., & Wang, Q. (2025) · Nonlinear Dynamics · doi:10.1007/s11071-025-11863-0 · Cited by 16
“Clinically, this framework suggests that therapeutic strategies targeting ionic regulation — particularly potassium channels and their associated pathways — may be as critical as synaptic interventions in controlling seizures [42].”
Current and emerging pharmacotherapies in Lennox-Gastaut syndrome
Samanta, D., & Nath, M. (2025) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2025.2516630 · Cited by 14
“2) may be addressed by emerging potassium channel openers, including XEN1101 and BHV-7000 [73].”
Metadata
- Authors
- Perucca, E., & Taglialatela, M.
- Affiliations
- The University of Melbourne (AU)
- University of Naples Federico II (IT)
- Corresponding author
- Perucca, Emilio
- Venue
- CNS Drugs
- Published
- 2025-01-24
- Volume
- 39
- Issue
- 3
- Pages
- 263-288
- ISSN
- 1172-7047 (ISSN-L)
- 1179-1934
- PMC
- PMC11850491
- OpenAlex
- W4406801261
- Cited by
- 43
- References
- 179
- Citations by year
- 2026: 27 · 2025: 16
- FWCI
- 7.62
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc
- creativecommons.org/licenses/by-nc/4.0 (tdm)
- creativecommons.org/licenses/by-nc/4.0 (vor)
- Locations
- CNS Drugs (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Minerva Access (University of Melbourne) (submittedVersion, cc-by-nc)
- Funders
- University of Melbourne
- Topics
- Health Sciences › Medicine › Clinical Neurology › Epilepsy research and treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ion channel regulation and function
- Health Sciences › Medicine › Physiology (medical) › Diet and metabolism studies
- Keywords
- Kv7 potassium channels, Kv7.2, Kv7.3, KCNQ2, epilepsy, antiepileptic drugs, retigabine, ezogabine, developmental and epileptic encephalopathy, major depressive disorder, generalized tonic-clonic seizures
- MeSH terms
- Animals, Anticonvulsants, Carbamates, Epilepsy, Humans, Phenylenediamines, KCNQ Potassium Channels, KCNQ2 Potassium Channel, KCNQ3 Potassium Channel
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Targeting Kv7 Potassium Channels for Epilepsy. https://app.cochat.ai/papers/10.1007/s40263-024-01155-3
- The paper
- Perucca, E., & Taglialatela, M. (2025). Targeting Kv7 Potassium Channels for Epilepsy. CNS Drugs. https://doi.org/10.1007/s40263-024-01155-3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.